ArticleMedicine2025
Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge.Diseases (Basel, Switzerland) · 2025Article
- Atypical hemolytic uremic syndrome associated with pregnancy: A case report.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAtypical hemolytic uremic syndrome (aHUS) is a severe rare disease characterized by microvascular hemolytic anemia, thrombocytopenia, and acute renal failure. PATIENT CONCERNS: A 10-year-old male presented with symptoms of weakness, jaundice, pallor, swollen eyelids, and no significant lower limb swelling. Laboratory investigations revealed critical hemoglobin levels, fragmented red blood cells, thrombocytopenia, and acute kidney injury. DIAGNOSES: The patient was diagnosed with aHUS based on the clinical trial of microvascular hemolytic anemia, thrombocytopenia, and organ damage due to thrombosis, as well as laboratory findings.
interventionsThe patient was treated with a combination of plasma exchange and the drug Eculizumab. Comprehensive nursing care was provided, including the establishment and maintenance of blood purification pipelines, management of complications (such as coagulation, allergic reactions, hypotension, and bleeding), and psychological support for the patient and family. OUTCOMES: The patient successfully completed a 3-month treatment regimen with Eculizumab and has been followed up for an additional 10 months without any recurrence of the condition, demonstrating favorable treatment outcomes. LESSONS: The novel approach of combining plasma exchange with Eculizumab in pediatric aHUS presents significant nursing challenges, but the case demonstrates the potential benefits of this combination therapy, particularly in the pediatric population in China where Eculizumab has recently become available. Comprehensive nursing care, including managing complications and providing psychological support, is crucial to the successful treatment of aHUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.